| Autor: |
Eliane Aparecida Rosseto-Welter, Leticia D’argenio-Garcia, Filipa Blasco Tavares Pereira Lopes, Ana Eduarda Zulim Carvalho, Fernando Flaquer, Vanessa Severo-Lemos, Claudia Concer Viero Nora, Flavio Steinwurz, Lucas Pires Garcia Oliveria, Thiago Aloia, Luiz Vicente Rizzo, Cristóvão Luis Pitangueira Mangueira, Karina Inacio Carvalho |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Canadian Journal of Gastroenterology and Hepatology, Vol 2022 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2291-2797 |
| DOI: |
10.1155/2022/1307159 |
| Popis: |
Crohn’s disease (CD) is a chronic inflammatory disease with a complex interface of broad factors. There are two main treatments for Chron’s disease: biological therapy and nonbiological therapy. Biological agent therapy (e.g., anti-TNF) is the most frequently prescribed treatment; however, it is not universally accessible. In fact, in Brazil, many patients are only given the option of receiving nonbiological therapy. This approach prolongs the subsequent clinical relapse; however, this procedure could be implicated in the immune response and enhance disease severity. Our purpose was to assess the effects of different treatments on CD4+ T cells in a cohort of patients with Crohn’s disease compared with healthy individuals. To examine the immune status in a Brazilian cohort, we analyzed CD4+ T cells, activation status, cytokine production, and Treg cells in blood of Crohn’s patients. Patients that underwent biological therapy can recover the percentage of CD4+CD73+ T cells, decrease the CD4+ T cell activation/effector functions, and maintain the peripheral percentage of regulatory T cells. These results show that anti-TNF agents can improve CD4+ T cell subsets, thereby inducing Crohn’s patients to relapse and remission rates. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text